Dr. Lal PathLabs First in India to Use AI for Cancer Diagnosis

India is experiencing a revolution in the diagnostic industry with Dr. Lal PathLabs becoming the first lab in the country to utilize deep learning based artificial intelligence module to detect lymph node metastasis including micro-metastasis in patients with cancer.

This technology, in association with Qritive, an organization based out of Singapore, was recently presented at USCAP 2025 which is one of the most popular pathology conferences in the world. Experts report that lymph node metastasis can only be successfully treated with the help of accurate detection in cancer staging and treatment planning. Possession of such signs may enable the disease to proceed; otherwise, no such signs could lead to low survival.

QiAI Lymph Node Dx, the AI-powered solution, speeds up and improves accuracy in identifying cancer cells on digital slides, especially micro-metastases, which are often overlooked during manual reviews.

"At Dr. Lal PathLabs, we are proud to lead the way in bringing AI-powered diagnostics to India," said Shankha Banerjee, CEO, Dr. Lal PathLabs. "This advanced technology allows us to identify cancer spread with exceptional precision and speed - particularly micrometastasis that may be missed by the human eye. By integrating AI into our pathology workflow, we are not only enhancing diagnostic accuracy but also enabling quicker clinical decisions, which can significantly improve treatment outcomes and quality of life for patients."

Also Read: How PLI Scheme is Reshaping India's Drug Production Future

The system was tested across breast, colon, stomach, and esophageal cancer cases, with findings validated through immunohistochemistry (IHC).

"The role of a pathologist is evolving rapidly, and we must evolve with it," said Dr. Vandana Lal, Executive Director, Dr Lal PathLabs. "This advancement strengthens our ability to identify even the most elusive signs of cancer… and a proud moment in our commitment to driving precision diagnostics in India."

The system was trained on breast, colon, stomach and esophageal cancer cases, results of which were verified by immunohistochemistry (IHC).